论文部分内容阅读
目的探讨沙利度胺联合胸腔内灌注重组人白细胞介素-2治疗肺癌合并恶性胸腔积液患者的临床疗效。方法选取2013年9月至2015年9月济阳县中医院収治的90例肺癌合并恶性胸腔积液患者作为研究对象,按随机数字表法将其分为对照组与观察组,每组45例。对照组患者给予胸腔闭式引流联合胸腔内灌注重组人白细胞介素-2治疗,观察组患者在对照组基础上口服沙利度胺,比较两组患者治疗前后血清血管内皮生长因子(VEGF)水平、临床疗效及不良反应发生情况。结果治疗后,观察组患者的血清VEGF水平明显低于对照组,差异有统计学意义(P<0.05);观察组患者的疾病控制率明显高于对照组,差异有统计学意义(P<0.05)。结论采用沙利度胺联合胸腔内灌注重组人白细胞介素-2治疗肺癌合并恶性胸腔积液临床效果显著,可通过降低血清VEGF水平,延缓疾病进展,且安全性高。
Objective To investigate the clinical efficacy of thalidomide in combination with intrathoracic infusion of recombinant human interleukin-2 in patients with lung cancer and malignant pleural effusion. Methods Ninety patients with malignant pleural effusion with lung cancer who were treated in Jiyang Hospital of Chinese Medicine from September 2013 to September 2015 were selected as the research objects and divided into control group and observation group according to random number table method. example. Patients in the control group received closed thoracic drainage and intrathoracic injection of recombinant human interleukin-2. Patients in the observation group were given oral thalidomide on the basis of the control group. The levels of serum vascular endothelial growth factor (VEGF) in the two groups were compared before and after treatment , Clinical efficacy and adverse reactions occurred. Results After treatment, the level of serum VEGF in the observation group was significantly lower than that in the control group (P <0.05). The disease control rate in the observation group was significantly higher than that in the control group (P <0.05 ). Conclusion Thalidomide combined with intrathoracic infusion of recombinant human interleukin-2 in the treatment of lung cancer complicated with malignant pleural effusion has a significant clinical effect. It can delay the progression of the disease by decreasing the level of serum VEGF, and is safe.